OClawVPS.com
Deerfield Management
Edit

Deerfield Management

http://www.deerfield.com/
Last activity: 26.02.2026
Active
Portfolio
7
Mentions
124
Investment Type: Venture Capital
Investment Stage: Series A; Series B

Portfolio 7

DateNameWebsiteTotal RaisedLocation
26.02.2026SHINE Medi...shinetechnologies.com$240MUnited Sta...
01.10.2025Axon Thera...axontherapies.com$32MUnited Sta...
06.01.2023Perceive B...perceivebio.com$78M-
05.10.2018Tris Pharm...trispharma.com$125MUnited Sta...
06.02.2017Chondrial ...chondrialtherapeutics.com$48.4M-
16.06.2016Blade Ther...blademed.com$45MUnited Sta...
03.04.2013WorldOneworldone.com$60MUnited Sta...

Mentions in press and media 124

DateTitleDescription
27.02.2026SHINE Technologies Secures $240M, Propelling Fusion and Medical Isotopes ForwardSHINE Technologies secured $240 million in new equity funding, pushing its total capital raised beyond $1 billion. Dr. Patrick Soon-Shiong, a noted biotech visionary, joined its Board of Directors. This substantial investment will vigorousl...
26.02.2026Shine Raises $240M in FundingShine Technologies, a Janesville, WI-based nuclear fusion company, raised $240M in equity funding. The round was led by NantWorks with additional participation from Fidelity Management and Research Company, Sumitomo Corporation of Americas,...
26.02.2026SHINE Technologies: $240 Million Raised For Nuclear Fusion And Medical Isotope ExpansionSHINE Technologies, a nuclear fusion company, announced it has raised $240 million in equity funding and appointed Dr. Patrick Soon-Shiong, M.D., Executive Chairman of ImmunityBio and founder of NantWorks, to its Board of Directors. The rou...
07.11.2025myLaurel Raises Funding For Advancing Expansion Of Hospital-Level Care In The HomeSteelSky Ventures has led a new investment round in myLaurel, joining Deerfield Management and Google Ventures (GV) to expand myLaurel’s in-home acute care platform across major U.S. health systems. The funding will support nationwide growt...
01.10.2025Axon Therapies: $32 Million Series A Secured For Developing Heart Failure TreatmentsAxon Therapies, a pioneering company in the medical device field, has announced the closure of an oversubscribed $32 million Series A funding round, focused on developing innovative treatments for heart failure. This funding round was co-le...
26.09.2025Axon Therapies Raises $32M in FundingCo-founder Zoar Engelman, PhD, appointed CEO of Axon Therapies Axon Therapeutics, a NYC-based clinical-stage medical device company, raised $32M in funding. The round was led by Earlybird Venture Capital and Santé Ventures, with participati...
27.08.2025Reprieve Cardiovascular Raises $61M in Series B FinancingReprieve Cardiovascular, a Milford, MA-based clinical-stage company pioneering intelligent decongestion management therapy for acute decompensated heart failure (ADHF), raised $61M in Series B funding. The round was led by Deerfield Managem...
13.08.2025Reprieve Cardiovascular Raises $61M to Fund Pivotal Heart Failure TrialWhat You Should Know: – Reprieve Cardiovascular, a clinical-stage company secures $61M in Series B funding led by Deerfield Management and included participation from several other investors, such as Arboretum Ventures, Lightstone Ventures,...
13.08.2025Reprieve Cardiovascular Secures $61 Million Financing and Enrolls First Patient in Pivotal Study— Series B fundraise led by Deerfield Management enables scaling of pivotal clinical trial and commercial readiness activities for Reprieve® System – First patient enrolled in FASTR II study by Washington University School of Medicine in St...
07.06.2025myLaurel: $12 Million Raised For Home-Based Acute And Transitional CaremyLaurel, a healthcare company delivering home-based acute and transitional care, announced it raised additional capital and held an initial closing of $12 million from existing investors. The funding round was led by Deerfield Management a...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In